Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Bellus Health Inc.
Headquarters: Laval, QC, Canada
Website: N/A
Year Founded: 1993
Status: Acquired
BioCentury | Jan 4, 2024
Deals
Parsing premiums: 2023’s biopharma M&A deals
2023’s highest-premium takeouts and its top-value deal all came early, but 4Q was notable for its pace of $1B+ deals
BioCentury | Oct 11, 2023
Data Byte
Where Mirati’s premium falls among M&A deals this year
Mature assets have been a theme among this year’s $1B+ takeouts, but Mirati fetched one of the lowest premiums despite its marketed product
BioCentury | Aug 25, 2023
Management Tracks
John Orwin named chairman at Cargo
Plus: Ramzi Benamar joins Elucida as CFO, and updates from Innoviva and Sarfez
BioCentury | May 10, 2023
Deals
How CTI found its target population and set itself up for a $1.7B takeout by Sobi
Swedish company pays 89% premium to add Vonjo to hematology portfolio, a year after its accelerated approval in a disease space dominated by Jakafi
BioCentury | May 1, 2023
Deals
Iveric takeout spotlights how Astellas builds in new areas of focus
The $5.9B ophthalmology deal also turns M&A attention to rival Apellis
BioCentury | Apr 18, 2023
Deals
Bellus’ focus on cough program pays off with $2B GSK buyout
Montreal biotech shed other programs, drove single asset through mid-stage trials to provoke takeout interest
BioCentury | Apr 15, 2022
Finance
Years after failed IPO attempts, Alzheon raises $50M round for Alzheimer’s study
With Phase III Alzheimer’s trial finally in progress, Alzheon’s new $50M series D arrives four years after first attempt to go public
BioCentury | Feb 15, 2022
Deals
With Bayer deal ended, Evotec mulls options, plots future with newer platforms
Unwinding of P2X3 deal leaves Evotec with choices as platforms fuel partnering-centric model
BioCentury | Feb 5, 2022
Deals
Evotec shares sag as Bayer terminates P2X3 program, returns rights
Bayer hands back P2X3 program to Evotec soon after Merck’s therapy hits regulatory snag
BioCentury | Dec 14, 2021
Product Development
Dec. 13 Quick Takes: Bellus headed for Phase III in chronic cough
Plus: Veru’s Entadfi approved, Brii asset on hold and updates from Arbutus, BrainStorm and Vaccitech
Items per page:
1 - 10 of 54